Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCSK9 cardiovascular vaccine
- Development stage
- Preclinical
- Lead developer
- AdaptVac
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
PCSK9 cardiovascular vaccine is a virus-like particle (VLP)-based therapeutic vaccine being developed by AdaptVac for the treatment of cardiovascular disease and hypercholesterolemia. Utilizing AdaptVac's proprietary capsid VLP (cVLP) platform, the vaccine displays PCSK9 antigens in a highly repetitive, virus-like array to trigger a potent and durable polyclonal antibody response. These induced endogenous antibodies bind to and neutralize circulating proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing it from binding to and promoting the degradation of low-density lipoprotein receptors (LDLR) on the surface of hepatocytes. By maintaining higher levels of LDLR, the vaccine facilitates increased clearance of LDL cholesterol from the bloodstream, potentially offering a long-acting alternative to monoclonal antibody therapies.
- Other names
- PCSK9-cVLP vaccinePCSK-9-cVLP vaccinePCSK 9-cVLP vaccineAdaptVac PCSK9 vaccine
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on PCSK9 cardiovascular vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCSK9 cardiovascular vaccine.